NASDAQ: DMAC - DiaMedica Therapeutics Inc.

Lønnsomhet i seks måneder: -20%
Utbytte: 0.00%
Sektor: Healthcare

Kampanjeplan DiaMedica Therapeutics Inc.

Avansert tidsplan Enkel graf
Financial Markets by TradingView

Om selskapet DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory diseases.

flere detaljer
The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Legg til i sammenligningslisten
Legg til overvåkningsliste
Legg til portefølje
Legg til prisvarsel

IPO date 2008-01-04
ISIN CA25253X2077
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.diamedica.com
Цена ао 4.08
Prisendring per dag: -0.565% (3.54)
Prisendring per uke: +4.14% (3.38)
Prisendring per måned: -38.99% (5.77)
Prisendring over 3 måneder: -29.88% (5.02)
Prisendring over seks måneder: -20% (4.4)
Prisendring per år: +47.28% (2.39)
Prisendring over 3 år: +56.44% (2.25)
Prisendring over 5 år: +15.79% (3.04)
Prisendring siden begynnelsen av året: -34.57% (5.38)
Alle parametere

Undervurdering

Navn Betydning Karakter
P/S 0 0
P/BV 1.82 8
P/E 0 0
EV/EBITDA -4.18 0
Total: 3.5

Effektivitet

Navn Betydning Karakter
ROA, % -35.78 0
ROE, % -37.96 0
Total: 0

Utbytte

Navn Betydning Karakter
Div yield, % 0 0
DSI 0 0
Total: 0

Plikt

Navn Betydning Karakter
Debt/EBITDA -0.0188 10
Total: 10

Vekstimpuls

Navn Betydning Karakter
Lønnsomhet Revenue, % 1375.75 10
Lønnsomhet Ebitda, % 80.45 9
Lønnsomhet EPS, % -33 0
Total: 7.6
Flere detaljer

Institusjoner Volum Dele, %
Cooperman, Leon G. 883623 2.33
Vanguard Group Inc 802171 2.11
Paragon Associates & Paragon Associates Ii Joint Venture 500000 1.32
Altium Capital Management, LP 287698 0.76
Bleichroeder LP 222317 0.59
Geode Capital Management, LLC 218778 0.58
Jacob Asset Management Of New York LLC 168730 0.44
Northern Trust Corporation 133633 0.35
Morgan Stanley 120995 0.32
First Manhattan Company 114744 0.3



Veileder Stillingstittel Betaling Fødselsår
Mr. Dietrich John Pauls MBA President, CEO & Director 818.61k 1971 (54 år)
Mr. Scott Kellen CPA CFO & Corporate Secretary 485.43k 1965 (60 år)
Dr. Ambarish Shah Ph.D. Chief Technology Officer N/A
Mr. Dominic R. Cundari Chief Commercial Officer N/A 1951 (74 år)
Mr. David J. Wambeke Chief Business Officer N/A 1984 (41 år)
Dr. Lorianne K. Masuoka M.D. Chief Medical Officer N/A 1961 (64 år)

Adresse: United States, Minneapolis. MN, 301 Carlson Parkway - åpne i Google maps, åpne Yandex-kart
Nettsted: https://www.diamedica.com